Vincristine, Irinotecan, and Bevacizumab in Relapsed Wilms Tumor With Diffuse Anaplasia

Amalia Schiavetti, Giulia Varrasso, Paola Collini, Anna Clerico

Research output: Contribution to journalArticle

Abstract

The prognosis of relapsed Wilms tumor (WT) with diffuse anaplasia is dismal, therefore, novel therapeutic strategies need to be explored. We reported on 2 consecutive cases with relapsed anaplastic WT who presented a partial response after 2 courses of vincristine, irinotecan, and bevacizumab association. This regimen may have a role in the treatment of patients with anaplastic advanced WT.

Original languageEnglish
Pages (from-to)331-333
Number of pages3
JournalJournal of Pediatric Hematology/Oncology
Volume40
Issue number4
DOIs
Publication statusPublished - May 2018

Fingerprint Dive into the research topics of 'Vincristine, Irinotecan, and Bevacizumab in Relapsed Wilms Tumor With Diffuse Anaplasia'. Together they form a unique fingerprint.

  • Cite this